NCT04538625: Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

NCT04538625
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients receiving any type of immunotherapy including but not limited to immune checkpoint inhibitors (i.e. cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), the programmed cell death protein-1 and its ligand (PD1/PDL1), & IL-2 cancer immunotherapy); Patients with ongoing irritable bowel syndrome (IBS) or colitis
https://ClinicalTrials.gov/show/NCT04538625

Comments are closed.

Up ↑